...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Recent patents on anti-cancer drug discovery >Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
【24h】

Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy

机译：程序性细胞死亡1 /程序性细胞死亡1配体封锁疗法的预测功效生物标志物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Inhibitors of immune check-point molecule, programmed cell death 1 (PD-1) and its ligand, programmed cell death ligand 1 (PD-L1) have attracted much attention in cancer immunotherapy recently due to their durable antitumor effects in various malignances, especially the advanced ones. Unfortunately, only a fraction of patients with advanced tumors could benefit from anti-PD-1/PD-L1 therapy, while others still worsened. The key to this point is that there are no efficient biomarkers for screening anti-PD-1/PD-L1-sensitive patients. In this review, we aim at summarizing the latest advances of anti-PD-1/PDL1 immunotherapy and the potential predictive efficacy biomarkers to provide evidences for identifying anti-PD-1/PDL1-sensitive patients. The present article also includes the patent review coverage on this topic.
机译：免疫检查点分子，程序性细胞死亡1（PD-1）及其配体，程序性细胞死亡配体1（PD-L1）抑制剂最近在癌症免疫治疗中受到了广泛关注，因为它们在各种恶性肿瘤中具有持久的抗肿瘤作用，尤其是先进的。不幸的是，只有一小部分患有晚期肿瘤的患者可以从抗PD-1 / PD-L1治疗中受益，而其他患者仍在恶化。关键是没有有效的生物标志物来筛选抗PD-1 / PD-L1敏感的患者。在这篇综述中，我们旨在总结抗PD-1 / PDL1免疫疗法的最新进展以及潜在的预测疗效生物标志物，以提供鉴定抗PD-1 / PDL1敏感患者的证据。本文还包括有关该主题的专利审查范围。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号